LifeStance Health Group, Inc. (LFST)
ÜberbewertetFundamental
58
Kurs
$12.03
Marktkapitalisierung
$4.57B
Teil 1 · Was das Unternehmen wert ist
Übersicht
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 19. September 2026 with claude-haiku-4-5 — shared with all users
Its behavioral health division has been adding outpatient mental-health locations across the US, competing market by market with LifeStance for the same commercially insured patients.
A privately held multi-state outpatient psychiatry and therapy group with 80+ clinics plus telehealth, competing for the same insured US patients and the same clinicians as LifeStance's hybrid clinic model.
A private national psychiatry practice in network with more than 60 US insurers, competing directly for the insurance-covered psychiatry and medication-management visits that are LifeStance's core revenue.
Offers insurance-covered virtual therapy and psychiatry to US consumers and employers, competing for the same outpatient mental-health visits that LifeStance delivers by telehealth.
A private platform that puts independent US therapists and psychiatrists in network with commercial payors, competing with LifeStance both for patients looking for an in-network clinician and for the clinicians themselves.
Through BetterHelp it is the largest virtual therapy brand in the US and is moving from cash-pay to insurance coverage, meeting LifeStance on the same outpatient therapy demand.
Bilanz & Liquidität
Umsatz
$1.58B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$51M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$110M
Gesamtes Eigenkapital
$1.52B
Gesamtverbindlichkeiten
$683M
Current Ratio
1.38
Zinsdeckungsgrad
7.75
Schulden/EBITDA
7.21
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$8.76
Aktueller Kurs
$12.03
Sicherheitsmarge
-37.4%
Innerer-Wert-Spanne
$5.69 - $11.82
Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
92.54
ROE
0.6%
P/B-Verhältnis
3.11
P/FCF
26.43
Bruttomarge
-
ROIC
3.3%
Rentabilitäts-Radar
Wertschöpfung (Wettbewerbsvorteil)
ROIC
3.3%
WACC
11.1%
ROIC − WACC
-7.8 pp
Der ROIC liegt unter den Kapitalkosten: Das Unternehmen vernichtet für jeden investierten Dollar Wert.
Fundamentalanalyse-Kriterien
Bestanden (13)
- EPS shows upward trend
- P/FCF 26.43
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Return on Tangible Assets
- Revenue Growth 5Y 30.4%
- Analyst Consensus 78% Buy
- Earnings Surprise avg 621.9%
- Earnings Quality (OCF/NI) 4.31
- Net Margin Trend 3.2% vs -1.2%
- Piotroski F-Score 7/9
Nicht bestanden (11)
- Price CAGR 4.88%
- ROIC 3.2%
- P/B Ratio 3.11
- Operating Margin 4.9%
- CapEx intensity
- Debt/EBITDA
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.4%
- Share Dilution 26.2%
Nicht verfügbar (3)
- Gross Margin NaN%
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Starke finanzielle Gesundheit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Neue Aktien werden ausgegeben, Eigentum wird verwässert
Institutionelle Beteiligungen
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Kenneth Alan Burdick J.D. | Executive Chairman | 66 |
| Mr. David Patrick Bourdon | CEO & Director | 56 |
| Mr. Ryan Bruce McGroarty | CFO & Treasurer | 52 |
| Mr. Vukasin Paunovich | Chief Technology Officer | 53 |
| Mr. Ryan Pardo J.D. | Chief Legal Officer & Secretary | 48 |
| Ms. Ann Varanakis | Chief People Officer | 47 |
| Ms. Lisa Keise Miller | Chief Operating Officer & Principal Operating Officer | 51 |
| Ms. Monica Prokocki | Vice President of Investor Relations | - |
| Brooke Matthews | Director of Public Relations | - |
| Mr. Richard Hall | Chief Shared Services Officer | - |
Prüfungsrisiko
10
Vorstandsrisiko
10
Vergütungsrisiko
7
Aktionärsrechterisiko
8
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Dokumente
- Dokument ansehen
Jahresbericht (10-K)
Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.
Eingereicht am 2026-02-25
- Dokument ansehen
Quartalsbericht (10-Q)
Ein Update zur finanziellen Entwicklung der letzten drei Monate.
Eingereicht am 2026-08-06
- Dokument ansehen
Ad-hoc-Meldung (8-K)
Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.
Eingereicht am 2026-09-11
via SEC EDGAR
Ertragshistorie
via SEC EDGAR
Latest News
Recent headlines for LFST, sourced from Markets Gazette.
- 2/25/2026NEUTRALLifeStance (LFST) Q4 2025 Earnings Call Transcript
The transcript for LifeStance Health Group, Inc.'s (LFST) Q4 2025 earnings call is now available. Investors and analysts have been keenly awaiting this document to gain in-depth insights into the company's financial performance for the period. While the specific content has not been disclosed in this announcement, the release of the transcript is a crucial event for market transparency. Market participants will now focus on analyzing management's statements, future projections, and responses to analyst questions to assess LifeStance's operational health and growth prospects. The market's reaction will hinge on the key metrics presented and the guidance provided.
via Markets Gazette